Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keefer

Showing results (1071-1080 of 1,129) with videos related to

Pageof 113
Sort By:
Journal of Medicinal Chemistry|December 22, 2005
Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in VivoKatrina M Miranda, Tatsuo Katori, Claudia L Torres de Holding, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
The Journal of Pediatrics|May 30, 2024
Mental Health Experiences of Adolescents and Young Adults with Inflammatory Bowel Disease During Transition to Adult Care: A Qualitative Descriptive StudyBrooke Allemang, Mira Browne, Melanie Barwick, et al.
Environmental Science & Technology|December 15, 2025
The US EPA's National Nutrient Inventory: Critical Shifts in US Nutrient Pollution Sources from 1987 to 2017Meredith M Brehob, Michael J Pennino, Jana E Compton, et al.
Ebiomedicine|February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
The Journal of Biological Chemistry|November 14, 2014
A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1/2αShu-jen Chen, Nicholas E Hoffman, Santhanam Shanmughapriya, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging studyPaul A Goepfert, Bo Fu, Anne-Laure Chabanon, et al.
Pageof 113

Showing results (1071-1080 of 1,129) with videos related to

Sort By:
Pageof 113
Journal of Medicinal Chemistry|December 22, 2005
Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in VivoKatrina M Miranda, Tatsuo Katori, Claudia L Torres de Holding, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
The Journal of Pediatrics|May 30, 2024
Mental Health Experiences of Adolescents and Young Adults with Inflammatory Bowel Disease During Transition to Adult Care: A Qualitative Descriptive StudyBrooke Allemang, Mira Browne, Melanie Barwick, et al.
Environmental Science & Technology|December 15, 2025
The US EPA's National Nutrient Inventory: Critical Shifts in US Nutrient Pollution Sources from 1987 to 2017Meredith M Brehob, Michael J Pennino, Jana E Compton, et al.
Ebiomedicine|February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
The Journal of Biological Chemistry|November 14, 2014
A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1/2αShu-jen Chen, Nicholas E Hoffman, Santhanam Shanmughapriya, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging studyPaul A Goepfert, Bo Fu, Anne-Laure Chabanon, et al.
Pageof 113